<DOC>
	<DOCNO>NCT02804178</DOCNO>
	<brief_summary>This Phase 2 multicenter , single-blind , multiple dose study evaluate safety efficacy orally administer ATR-101 subject classic congenital adrenal hyperplasia ( CAH ) . Treatment duration range minimum approximately 2 month 6 month per subject . A subject may receive minimum one dose level maximum 5 dose level , sequentially increase dose strength . Each dose level last 28 day .</brief_summary>
	<brief_title>A Study ATR-101 Treatment Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Documented historical diagnosis classic CAH due 21OHD base : Documented genetic mutation CYP21A2 enzyme consistent diagnosis classic CAH , historical documentation elevate 17OHP Biochemical marker disease status 17OHP â‰¥ 4 X ULN Chronic glucocorticoid replacement therapy least 6 consecutive month Stable glucocorticoid mineralocorticoid regimen least 1 month Nonclassic CAH Other cause adrenal insufficiency Surgery within previous 3 month prior screen plan surgery study participation History active cancer require medical surgical therapy within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ATR-101</keyword>
	<keyword>classic congenital adrenal hyperplasia</keyword>
	<keyword>21-hydroxylase deficiency</keyword>
	<keyword>CAH</keyword>
</DOC>